世界の網膜用バイオシミラー市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Retinal Biosimilars Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4822 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、網膜用バイオシミラーの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（黄斑変性症薬、糖尿病性眼疾患薬、黄斑パッカー薬、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・網膜用バイオシミラーの市場動向 ・企業の競争状況、市場シェア ・網膜用バイオシミラーの種類別市場規模と予測2016-2027（黄斑変性症薬、糖尿病性眼疾患薬、黄斑パッカー薬、その他） ・網膜用バイオシミラーの用途別市場規模と予測2016-2027（病院薬局、小売薬局、オンライン薬局） ・網膜用バイオシミラーの北米市場規模2016-2027（アメリカ、カナダ） ・網膜用バイオシミラーの欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・網膜用バイオシミラーのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・網膜用バイオシミラーの中南米市場規模2016-2027（メキシコ、ブラジル） ・網膜用バイオシミラーの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Novartis (Sandoz)、Takeda、Bayer、Genentech、Pfenex、Reliance Life Sciences、Hetero Drugs、Intas Pharmaceuticals、Santo Holding、Regeneron Pharmaceuticals） ・結論

Market Analysis and Insights: Global Retinal Biosimilars Market
The global Retinal Biosimilars market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Retinal Biosimilars market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Retinal Biosimilars market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Retinal Biosimilars market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Retinal Biosimilars market.

Global Retinal Biosimilars Scope and Market Size
Retinal Biosimilars market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Retinal Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Macular Degeneration Drugs
Diabetic Eye Disease Drugs
Macular Pucker Drugs
Others

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis (Sandoz)
Takeda
Bayer
Genentech
Pfenex
Reliance Life Sciences
Hetero Drugs
Intas Pharmaceuticals
Santo Holding
Regeneron Pharmaceuticals

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Retinal Biosimilars Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Macular Degeneration Drugs
1.2.3 Diabetic Eye Disease Drugs
1.2.4 Macular Pucker Drugs
1.2.5 Others
1.3 Market by Application
1.3.1 Global Retinal Biosimilars Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Retinal Biosimilars Market Perspective (2016-2027)
2.2 Retinal Biosimilars Growth Trends by Regions
2.2.1 Retinal Biosimilars Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Retinal Biosimilars Historic Market Share by Regions (2016-2021)
2.2.3 Retinal Biosimilars Forecasted Market Size by Regions (2022-2027)
2.3 Retinal Biosimilars Industry Dynamic
2.3.1 Retinal Biosimilars Market Trends
2.3.2 Retinal Biosimilars Market Drivers
2.3.3 Retinal Biosimilars Market Challenges
2.3.4 Retinal Biosimilars Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Retinal Biosimilars Players by Revenue
3.1.1 Global Top Retinal Biosimilars Players by Revenue (2016-2021)
3.1.2 Global Retinal Biosimilars Revenue Market Share by Players (2016-2021)
3.2 Global Retinal Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Retinal Biosimilars Revenue
3.4 Global Retinal Biosimilars Market Concentration Ratio
3.4.1 Global Retinal Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Retinal Biosimilars Revenue in 2020
3.5 Retinal Biosimilars Key Players Head office and Area Served
3.6 Key Players Retinal Biosimilars Product Solution and Service
3.7 Date of Enter into Retinal Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Retinal Biosimilars Breakdown Data by Type
4.1 Global Retinal Biosimilars Historic Market Size by Type (2016-2021)
4.2 Global Retinal Biosimilars Forecasted Market Size by Type (2022-2027)

5 Retinal Biosimilars Breakdown Data by Application
5.1 Global Retinal Biosimilars Historic Market Size by Application (2016-2021)
5.2 Global Retinal Biosimilars Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Retinal Biosimilars Market Size (2016-2027)
6.2 North America Retinal Biosimilars Market Size by Type
6.2.1 North America Retinal Biosimilars Market Size by Type (2016-2021)
6.2.2 North America Retinal Biosimilars Market Size by Type (2022-2027)
6.2.3 North America Retinal Biosimilars Market Size by Type (2016-2027)
6.3 North America Retinal Biosimilars Market Size by Application
6.3.1 North America Retinal Biosimilars Market Size by Application (2016-2021)
6.3.2 North America Retinal Biosimilars Market Size by Application (2022-2027)
6.3.3 North America Retinal Biosimilars Market Size by Application (2016-2027)
6.4 North America Retinal Biosimilars Market Size by Country
6.4.1 North America Retinal Biosimilars Market Size by Country (2016-2021)
6.4.2 North America Retinal Biosimilars Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Retinal Biosimilars Market Size (2016-2027)
7.2 Europe Retinal Biosimilars Market Size by Type
7.2.1 Europe Retinal Biosimilars Market Size by Type (2016-2021)
7.2.2 Europe Retinal Biosimilars Market Size by Type (2022-2027)
7.2.3 Europe Retinal Biosimilars Market Size by Type (2016-2027)
7.3 Europe Retinal Biosimilars Market Size by Application
7.3.1 Europe Retinal Biosimilars Market Size by Application (2016-2021)
7.3.2 Europe Retinal Biosimilars Market Size by Application (2022-2027)
7.3.3 Europe Retinal Biosimilars Market Size by Application (2016-2027)
7.4 Europe Retinal Biosimilars Market Size by Country
7.4.1 Europe Retinal Biosimilars Market Size by Country (2016-2021)
7.4.2 Europe Retinal Biosimilars Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Retinal Biosimilars Market Size (2016-2027)
8.2 Asia-Pacific Retinal Biosimilars Market Size by Type
8.2.1 Asia-Pacific Retinal Biosimilars Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Retinal Biosimilars Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Retinal Biosimilars Market Size by Type (2016-2027)
8.3 Asia-Pacific Retinal Biosimilars Market Size by Application
8.3.1 Asia-Pacific Retinal Biosimilars Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Retinal Biosimilars Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Retinal Biosimilars Market Size by Application (2016-2027)
8.4 Asia-Pacific Retinal Biosimilars Market Size by Region
8.4.1 Asia-Pacific Retinal Biosimilars Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Retinal Biosimilars Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Retinal Biosimilars Market Size (2016-2027)
9.2 Latin America Retinal Biosimilars Market Size by Type
9.2.1 Latin America Retinal Biosimilars Market Size by Type (2016-2021)
9.2.2 Latin America Retinal Biosimilars Market Size by Type (2022-2027)
9.2.3 Latin America Retinal Biosimilars Market Size by Type (2016-2027)
9.3 Latin America Retinal Biosimilars Market Size by Application
9.3.1 Latin America Retinal Biosimilars Market Size by Application (2016-2021)
9.3.2 Latin America Retinal Biosimilars Market Size by Application (2022-2027)
9.3.3 Latin America Retinal Biosimilars Market Size by Application (2016-2027)
9.4 Latin America Retinal Biosimilars Market Size by Country
9.4.1 Latin America Retinal Biosimilars Market Size by Country (2016-2021)
9.4.2 Latin America Retinal Biosimilars Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Retinal Biosimilars Market Size (2016-2027)
10.2 Middle East & Africa Retinal Biosimilars Market Size by Type
10.2.1 Middle East & Africa Retinal Biosimilars Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Retinal Biosimilars Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Retinal Biosimilars Market Size by Type (2016-2027)
10.3 Middle East & Africa Retinal Biosimilars Market Size by Application
10.3.1 Middle East & Africa Retinal Biosimilars Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Retinal Biosimilars Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Retinal Biosimilars Market Size by Application (2016-2027)
10.4 Middle East & Africa Retinal Biosimilars Market Size by Country
10.4.1 Middle East & Africa Retinal Biosimilars Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Retinal Biosimilars Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novartis (Sandoz)
11.1.1 Novartis (Sandoz) Company Details
11.1.2 Novartis (Sandoz) Business Overview
11.1.3 Novartis (Sandoz) Retinal Biosimilars Introduction
11.1.4 Novartis (Sandoz) Revenue in Retinal Biosimilars Business (2016-2021)
11.1.5 Novartis (Sandoz) Recent Development
11.2 Takeda
11.2.1 Takeda Company Details
11.2.2 Takeda Business Overview
11.2.3 Takeda Retinal Biosimilars Introduction
11.2.4 Takeda Revenue in Retinal Biosimilars Business (2016-2021)
11.2.5 Takeda Recent Development
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer Retinal Biosimilars Introduction
11.3.4 Bayer Revenue in Retinal Biosimilars Business (2016-2021)
11.3.5 Bayer Recent Development
11.4 Genentech
11.4.1 Genentech Company Details
11.4.2 Genentech Business Overview
11.4.3 Genentech Retinal Biosimilars Introduction
11.4.4 Genentech Revenue in Retinal Biosimilars Business (2016-2021)
11.4.5 Genentech Recent Development
11.5 Pfenex
11.5.1 Pfenex Company Details
11.5.2 Pfenex Business Overview
11.5.3 Pfenex Retinal Biosimilars Introduction
11.5.4 Pfenex Revenue in Retinal Biosimilars Business (2016-2021)
11.5.5 Pfenex Recent Development
11.6 Reliance Life Sciences
11.6.1 Reliance Life Sciences Company Details
11.6.2 Reliance Life Sciences Business Overview
11.6.3 Reliance Life Sciences Retinal Biosimilars Introduction
11.6.4 Reliance Life Sciences Revenue in Retinal Biosimilars Business (2016-2021)
11.6.5 Reliance Life Sciences Recent Development
11.7 Hetero Drugs
11.7.1 Hetero Drugs Company Details
11.7.2 Hetero Drugs Business Overview
11.7.3 Hetero Drugs Retinal Biosimilars Introduction
11.7.4 Hetero Drugs Revenue in Retinal Biosimilars Business (2016-2021)
11.7.5 Hetero Drugs Recent Development
11.8 Intas Pharmaceuticals
11.8.1 Intas Pharmaceuticals Company Details
11.8.2 Intas Pharmaceuticals Business Overview
11.8.3 Intas Pharmaceuticals Retinal Biosimilars Introduction
11.8.4 Intas Pharmaceuticals Revenue in Retinal Biosimilars Business (2016-2021)
11.8.5 Intas Pharmaceuticals Recent Development
11.9 Santo Holding
11.9.1 Santo Holding Company Details
11.9.2 Santo Holding Business Overview
11.9.3 Santo Holding Retinal Biosimilars Introduction
11.9.4 Santo Holding Revenue in Retinal Biosimilars Business (2016-2021)
11.9.5 Santo Holding Recent Development
11.10 Regeneron Pharmaceuticals
11.10.1 Regeneron Pharmaceuticals Company Details
11.10.2 Regeneron Pharmaceuticals Business Overview
11.10.3 Regeneron Pharmaceuticals Retinal Biosimilars Introduction
11.10.4 Regeneron Pharmaceuticals Revenue in Retinal Biosimilars Business (2016-2021)
11.10.5 Regeneron Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Retinal Biosimilars Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Macular Degeneration Drugs
Table 3. Key Players of Diabetic Eye Disease Drugs
Table 4. Key Players of Macular Pucker Drugs
Table 5. Key Players of Others
Table 6. Global Retinal Biosimilars Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Retinal Biosimilars Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Retinal Biosimilars Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Retinal Biosimilars Market Share by Regions (2016-2021)
Table 10. Global Retinal Biosimilars Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Retinal Biosimilars Market Share by Regions (2022-2027)
Table 12. Retinal Biosimilars Market Trends
Table 13. Retinal Biosimilars Market Drivers
Table 14. Retinal Biosimilars Market Challenges
Table 15. Retinal Biosimilars Market Restraints
Table 16. Global Retinal Biosimilars Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Retinal Biosimilars Market Share by Players (2016-2021)
Table 18. Global Top Retinal Biosimilars Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Retinal Biosimilars as of 2020)
Table 19. Ranking of Global Top Retinal Biosimilars Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Retinal Biosimilars Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Retinal Biosimilars Product Solution and Service
Table 23. Date of Enter into Retinal Biosimilars Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Retinal Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Retinal Biosimilars Revenue Market Share by Type (2016-2021)
Table 27. Global Retinal Biosimilars Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Retinal Biosimilars Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Retinal Biosimilars Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Retinal Biosimilars Revenue Market Share by Application (2016-2021)
Table 31. Global Retinal Biosimilars Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Retinal Biosimilars Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Retinal Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Retinal Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Retinal Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Retinal Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Retinal Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Retinal Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Retinal Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Retinal Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Retinal Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Retinal Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Retinal Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Retinal Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Retinal Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Retinal Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Retinal Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Retinal Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Retinal Biosimilars Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Retinal Biosimilars Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Retinal Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Retinal Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Retinal Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Retinal Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Retinal Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Retinal Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Retinal Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Retinal Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Retinal Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Retinal Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Retinal Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Retinal Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 63. Novartis (Sandoz) Company Details
Table 64. Novartis (Sandoz) Business Overview
Table 65. Novartis (Sandoz) Retinal Biosimilars Product
Table 66. Novartis (Sandoz) Revenue in Retinal Biosimilars Business (2016-2021) & (US$ Million)
Table 67. Novartis (Sandoz) Recent Development
Table 68. Takeda Company Details
Table 69. Takeda Business Overview
Table 70. Takeda Retinal Biosimilars Product
Table 71. Takeda Revenue in Retinal Biosimilars Business (2016-2021) & (US$ Million)
Table 72. Takeda Recent Development
Table 73. Bayer Company Details
Table 74. Bayer Business Overview
Table 75. Bayer Retinal Biosimilars Product
Table 76. Bayer Revenue in Retinal Biosimilars Business (2016-2021) & (US$ Million)
Table 77. Bayer Recent Development
Table 78. Genentech Company Details
Table 79. Genentech Business Overview
Table 80. Genentech Retinal Biosimilars Product
Table 81. Genentech Revenue in Retinal Biosimilars Business (2016-2021) & (US$ Million)
Table 82. Genentech Recent Development
Table 83. Pfenex Company Details
Table 84. Pfenex Business Overview
Table 85. Pfenex Retinal Biosimilars Product
Table 86. Pfenex Revenue in Retinal Biosimilars Business (2016-2021) & (US$ Million)
Table 87. Pfenex Recent Development
Table 88. Reliance Life Sciences Company Details
Table 89. Reliance Life Sciences Business Overview
Table 90. Reliance Life Sciences Retinal Biosimilars Product
Table 91. Reliance Life Sciences Revenue in Retinal Biosimilars Business (2016-2021) & (US$ Million)
Table 92. Reliance Life Sciences Recent Development
Table 93. Hetero Drugs Company Details
Table 94. Hetero Drugs Business Overview
Table 95. Hetero Drugs Retinal Biosimilars Product
Table 96. Hetero Drugs Revenue in Retinal Biosimilars Business (2016-2021) & (US$ Million)
Table 97. Hetero Drugs Recent Development
Table 98. Intas Pharmaceuticals Company Details
Table 99. Intas Pharmaceuticals Business Overview
Table 100. Intas Pharmaceuticals Revenue in Retinal Biosimilars Business (2016-2021) & (US$ Million)
Table 101. Intas Pharmaceuticals Recent Development
Table 102. Santo Holding Company Details
Table 103. Santo Holding Business Overview
Table 104. Santo Holding Retinal Biosimilars Product
Table 105. Santo Holding Revenue in Retinal Biosimilars Business (2016-2021) & (US$ Million)
Table 106. Santo Holding Recent Development
Table 107. Regeneron Pharmaceuticals Company Details
Table 108. Regeneron Pharmaceuticals Business Overview
Table 109. Regeneron Pharmaceuticals Retinal Biosimilars Product
Table 110. Regeneron Pharmaceuticals Revenue in Retinal Biosimilars Business (2016-2021) & (US$ Million)
Table 111. Regeneron Pharmaceuticals Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Retinal Biosimilars Market Share by Type: 2020 VS 2027
Figure 2. Macular Degeneration Drugs Features
Figure 3. Diabetic Eye Disease Drugs Features
Figure 4. Macular Pucker Drugs Features
Figure 5. Others Features
Figure 6. Global Retinal Biosimilars Market Share by Application: 2020 VS 2027
Figure 7. Hospital Pharmacies Case Studies
Figure 8. Retail Pharmacies Case Studies
Figure 9. Online Pharmacies Case Studies
Figure 10. Retinal Biosimilars Report Years Considered
Figure 11. Global Retinal Biosimilars Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Retinal Biosimilars Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Retinal Biosimilars Market Share by Regions: 2020 VS 2027
Figure 14. Global Retinal Biosimilars Market Share by Regions (2022-2027)
Figure 15. Global Retinal Biosimilars Market Share by Players in 2020
Figure 16. Global Top Retinal Biosimilars Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Retinal Biosimilars as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Retinal Biosimilars Revenue in 2020
Figure 18. Global Retinal Biosimilars Revenue Market Share by Type (2016-2021)
Figure 19. Global Retinal Biosimilars Revenue Market Share by Type (2022-2027)
Figure 20. North America Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Retinal Biosimilars Market Share by Type (2016-2027)
Figure 22. North America Retinal Biosimilars Market Share by Application (2016-2027)
Figure 23. North America Retinal Biosimilars Market Share by Country (2016-2027)
Figure 24. United States Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Retinal Biosimilars Market Share by Type (2016-2027)
Figure 28. Europe Retinal Biosimilars Market Share by Application (2016-2027)
Figure 29. Europe Retinal Biosimilars Market Share by Country (2016-2027)
Figure 30. Germany Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Retinal Biosimilars Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Retinal Biosimilars Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Retinal Biosimilars Market Share by Region (2016-2027)
Figure 40. China Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Retinal Biosimilars Market Share by Type (2016-2027)
Figure 48. Latin America Retinal Biosimilars Market Share by Application (2016-2027)
Figure 49. Latin America Retinal Biosimilars Market Share by Country (2016-2027)
Figure 50. Mexico Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Retinal Biosimilars Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Retinal Biosimilars Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Retinal Biosimilars Market Share by Country (2016-2027)
Figure 56. Turkey Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Retinal Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Novartis (Sandoz) Revenue Growth Rate in Retinal Biosimilars Business (2016-2021)
Figure 60. Takeda Revenue Growth Rate in Retinal Biosimilars Business (2016-2021)
Figure 61. Bayer Revenue Growth Rate in Retinal Biosimilars Business (2016-2021)
Figure 62. Genentech Revenue Growth Rate in Retinal Biosimilars Business (2016-2021)
Figure 63. Pfenex Revenue Growth Rate in Retinal Biosimilars Business (2016-2021)
Figure 64. Reliance Life Sciences Revenue Growth Rate in Retinal Biosimilars Business (2016-2021)
Figure 65. Hetero Drugs Revenue Growth Rate in Retinal Biosimilars Business (2016-2021)
Figure 66. Intas Pharmaceuticals Revenue Growth Rate in Retinal Biosimilars Business (2016-2021)
Figure 67. Santo Holding Revenue Growth Rate in Retinal Biosimilars Business (2016-2021)
Figure 68. Regeneron Pharmaceuticals Revenue Growth Rate in Retinal Biosimilars Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

---